Recent Quotes (30 days)

You have no recent quotes
chg | %

Medovex Corp  

(Public, NASDAQ:MDVXU)   Watch this stock  
Find more results for MDVXU
5.84
+0.09 (1.57%)
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.75 - 6.75
52 week 5.75 - 6.75
Open 6.17
Vol. 880,077.00
Mkt cap 8.13M
P/E     -
Div/yield     -
EPS     -
Shares 1.39M
Beta     -
Inst. own     -
Sep 11, 2017
Medovex Corp at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -1165.88% -
Operating margin -1164.48% -
EBITD margin - -
Return on average assets -289.50% -204.19%
Return on average equity -391.56% -278.09%
Employees 5 -
CDP Score - -

Address

3060 Royal Blvd S Ste 150
ALPHARETTA, GA 30022-1418
United States - Map
+1-404-3936989 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Medovex Corp. is a development-stage company. The Company focuses on obtaining, developing and commercializing various intellectual property rights (patents, patent applications and knowhow) in the medical technology area, with particular focus on the development of medical devices. It focuses on development and commercialization of the DenerveX System, which consists of the DenerveX Device and the DenerveX Pro-40 power generator (DenerveX). DenerveX is a device that is intended to be used in the treatment of conditions resulting from the degeneration of joints in the spine that cause back pain. The DenerveX Pro-40 Power Generator is the power source for the DenerveX System. The system works in synchronization to deliver controlled and precise therapy to patients with facet joint pain. DenerveX combines two procedures in one: capsular tissue removal through a light tissue scraping action and radio ablation denervation. DenerveX is commercially not available in the United States.

Officers and directors

Jesse Crowne Executive Co-Chairman of the Board
Age: 33
Bio & Compensation  - Reuters
Larry W. Papasan Co-Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Patrick Kullmann President, Chief Operating Officer
Age: 61
Bio & Compensation  - Reuters
Jarrett Gorlin Chief Executive Officer, Director
Age: 40
Bio & Compensation  - Reuters
Charles Duane Farrahar Chief Financial Officer, Company Secretary
Age: 56
Bio & Compensation  - Reuters
Dennis Moon Senior Vice President
Age: 41
Bio & Compensation  - Reuters
James R. Andrews M.D. Director
Age: 74
Bio & Compensation  - Reuters
Randal R. Betz M.D. Director
Age: 59
Bio & Compensation  - Reuters
Ron Lawson Director
Age: 72
Bio & Compensation  - Reuters
Jon Mogford Ph.D. Director
Age: 49
Bio & Compensation  - Reuters